Mersana Axes Lead ADC Compound, Puts All Its Eggs In NaPi2b Basket

 
• By Jo Shorthouse

Mersana Therapeutics has discontinued its lead candidate because of the competitive landscape surrounding HER2-targeted therapies, and will refocus on its only other clinical program, the NaPi2b-targetting ADC XMT-1536 for ovarian cancer and NSCLC.

Bins
Mersana's lead candidate has been put out with the bins • Source: Shutterstock

More from Anticancer

More from Therapy Areas